[company_age]unknown[/company_age][employees]2-10 employees[/employees][description]MinervaX ApS is a Danish biotechnology company dedicated to developing a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threatening infections caused by Group B streptococcus (GBS). The company's vaccine is based on adjuvanted protein antigens covering close to 100% of clinical GBS isolates, making it a potentially superior alternative to traditional capsular polysaccharide (CPS) conjugate technology. MinervaX's vaccine has demonstrated efficacy in animal models and has completed Phase I trials in healthy adults, demonstrating a favorable safety profile and high levels of long-lasting functionally active antibodies. The company is currently conducting Phase II clinical trials in pregnant women in South Africa, Uganda, Denmark, and the United Kingdom. MinervaX's vaccine has the potential to significantly reduce the global burden of GBS-related neonatal infections and improve maternal and infant health outcomes.[/description][ps]Maternal vaccine for the prevention of Group B Streptococcus (GBS) infections in newborns[/ps]